These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25527611)

  • 1. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12.
    Melero I; Quetglas JI; Reboredo M; Dubrot J; Rodriguez-Madoz JR; Mancheño U; Casales E; Riezu-Boj JI; Ruiz-Guillen M; Ochoa MC; Sanmamed MF; Thieblemont N; Smerdou C; Hervas-Stubbs S
    Cancer Res; 2015 Feb; 75(3):497-507. PubMed ID: 25527611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography.
    Asselin-Paturel C; Lassau N; Guinebretière JM; Zhang J; Gay F; Bex F; Hallez S; Leclere J; Peronneau P; Mami-Chouaib F; Chouaib S
    Gene Ther; 1999 Apr; 6(4):606-15. PubMed ID: 10476220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication.
    Huarte E; Larrea E; Hernández-Alcoceba R; Alfaro C; Murillo O; Arina A; Tirapu I; Azpilicueta A; Hervás-Stubbs S; Bortolanza S; Pérez-Gracia JL; Civeira MP; Prieto J; Riezu-Boj JI; Melero I
    Mol Ther; 2006 Jul; 14(1):129-38. PubMed ID: 16627004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade.
    Quetglas JI; Labiano S; Aznar MÁ; Bolaños E; Azpilikueta A; Rodriguez I; Casales E; Sánchez-Paulete AR; Segura V; Smerdou C; Melero I
    Cancer Immunol Res; 2015 May; 3(5):449-54. PubMed ID: 25691326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA.
    Yamanaka R; Zullo SA; Tanaka R; Blaese M; Xanthopoulos KG
    J Neurosurg; 2001 Mar; 94(3):474-81. PubMed ID: 11235953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA.
    Yamanaka R; Yajima N; Tsuchiya N; Honma J; Tanaka R; Ramsey J; Blaese M; Xanthopoulos KG
    J Neurosurg; 2002 Nov; 97(5):1184-90. PubMed ID: 12450042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
    Sánchez-Paulete AR; Teijeira Á; Quetglas JI; Rodríguez-Ruiz ME; Sánchez-Arráez Á; Labiano S; Etxeberria I; Azpilikueta A; Bolaños E; Ballesteros-Briones MC; Casares N; Quezada SA; Berraondo P; Sancho D; Smerdou C; Melero I
    Cancer Res; 2018 Dec; 78(23):6643-6654. PubMed ID: 30297531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12.
    Yamanaka R; Zullo SA; Tanaka R; Ramsey J; Blaese M; Xanthopoulos KG
    Neurosurg Focus; 2000 Dec; 9(6):e7. PubMed ID: 16817690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12.
    Riezebos-Brilman A; Regts J; Chen M; Wilschut J; Daemen T
    Vaccine; 2009 Jan; 27(5):701-7. PubMed ID: 19041356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12.
    Yamanaka R; Zullo SA; Ramsey J; Yajima N; Tsuchiya N; Tanaka R; Blaese M; Xanthopoulos KG
    J Neurosurg; 2002 Sep; 97(3):611-8. PubMed ID: 12296646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12.
    Yamanaka R; Tsuchiya N; Yajima N; Honma J; Hasegawa H; Tanaka R; Ramsey J; Blaese RM; Xanthopoulos KG
    J Neurosurg; 2003 Oct; 99(4):746-53. PubMed ID: 14567611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.
    Dubrot J; Palazón A; Alfaro C; Azpilikueta A; Ochoa MC; Rouzaut A; Martinez-Forero I; Teijeira A; Berraondo P; Le Bon A; Hervás-Stubbs S; Melero I
    Int J Cancer; 2011 Jan; 128(1):105-18. PubMed ID: 20309938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing.
    Eguchi J; Hiroishi K; Ishii S; Mitamura K
    Cancer Immunol Immunother; 2003 Jun; 52(6):378-86. PubMed ID: 12739068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
    Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
    Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer.
    Li S; Zhang L; Torrero M; Cannon M; Barret R
    Mol Ther; 2005 Nov; 12(5):942-9. PubMed ID: 15953768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses.
    Waibler Z; Anzaghe M; Ludwig H; Akira S; Weiss S; Sutter G; Kalinke U
    J Virol; 2007 Nov; 81(22):12102-10. PubMed ID: 17855554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Semliki forest virus vector engineered to express IFNα induces efficient elimination of established tumors.
    Quetglas JI; Fioravanti J; Ardaiz N; Medina-Echeverz J; Baraibar I; Prieto J; Smerdou C; Berraondo P
    Gene Ther; 2012 Mar; 19(3):271-8. PubMed ID: 21734727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of liver-implanted tumors by Semliki Forest virus expressing IL-12 requires efficient long-term immune responses.
    Quetglas JI; Rodriguez-Madoz JR; Bezunartea J; Ruiz-Guillen M; Casales E; Medina-Echeverz J; Prieto J; Berraondo P; Hervas-Stubbs S; Smerdou C
    J Immunol; 2013 Mar; 190(6):2994-3004. PubMed ID: 23401594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity.
    Péron JM; Bureau C; Gourdy P; Lulka H; Souque A; Calippe B; Selves J; Al Saati T; Bernad J; Cordelier P; Couderc B; Pradayrol L; Pipy B; Buscail L; Vinel JP
    Gut; 2007 Jan; 56(1):107-14. PubMed ID: 16891358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term intratumoral interleukin-12 expressed from an alphaviral vector is sufficient to induce an efficient antitumoral response against spontaneous hepatocellular carcinomas.
    Rodriguez-Madoz JR; Zabala M; Alfaro M; Prieto J; Kramer MG; Smerdou C
    Hum Gene Ther; 2014 Feb; 25(2):132-43. PubMed ID: 24219025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.